Based on the VistaGen Therapeutics Inc stock forecast from 1 analysts, the average analyst target price for VistaGen Therapeutics Inc is USD 12.00 over the next 12 months. VistaGen Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of VistaGen Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, VistaGen Therapeutics Inc’s stock price was USD 2.17. VistaGen Therapeutics Inc’s stock price has changed by -13.20% over the past week, -21.38% over the past month and -58.03% over the last year.
No recent analyst target price found for VistaGen Therapeutics Inc
No recent average analyst rating found for VistaGen Therapeutics Inc
Company Overview VistaGen Therapeutics Inc
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Read Less
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the ...Read More
Frequently Asked Questions About VistaGen Therapeutics Inc (VTGN) Stock
Based on ratings from 1 analysts VistaGen Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on VTGN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for VTGN is USD 12.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on VTGN's stock to indicate if its overvalued.
The last closing price of VTGN's stock was USD 2.17.
The most recent market capitalization for VTGN is USD 0.08B.
Based on targets from 1 analysts, the average taret price for VTGN is projected at USD 12.00 over the next 12 months.
This means that VTGN's stock price may go up by +453.00% over the next 12 months.
We can't find any ETFs which contains VistaGen Therapeutics Inc's stock.
As per our most recent records VistaGen Therapeutics Inc has 48 Employees.
VistaGen Therapeutics Inc's registered address is 343 Allerton Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from VistaGen Therapeutics Inc's website at https://www.vistagen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About VistaGen Therapeutics Inc (VTGN) Stock
Based on ratings from 1 analysts VistaGen Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on VTGN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for VTGN is USD 12.00 over the next 12 months. The maximum analyst target price is USD 12 while the minimum anlayst target price is USD 12.
Unfortunately we do not have enough data on VTGN's stock to indicate if its overvalued.
The last closing price of VTGN's stock was USD 2.17.
The most recent market capitalization for VTGN is USD 0.08B.
Based on targets from 1 analysts, the average taret price for VTGN is projected at USD 12.00 over the next 12 months.
This means that VTGN's stock price may go up by +453.00% over the next 12 months.
We can't find any ETFs which contains VistaGen Therapeutics Inc's stock.
As per our most recent records VistaGen Therapeutics Inc has 48 Employees.
VistaGen Therapeutics Inc's registered address is 343 Allerton Avenue, South San Francisco, CA, United States, 94080.
You can get more information about it from VistaGen Therapeutics Inc's website at https://www.vistagen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VTGN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
